AstraZeneca Pharma India Limited — Important, 14-04-2025: General Updates

The company has received a final order from the Hon’ble Income-tax Appellate Tribunal regarding the assessment year 2014-15, resulting in significant tax adjustments related to transfer pricing and corporate tax issues being deleted. This ruling provides an expected tax relief of approximately ₹35.22 crore (cr), excluding interest. The settlement marks a positive development for the company, alleviating potential financial liabilities and enhancing its financial standing. Investors should regard this outcome as a favorable adjustment, contributing to a strengthened position moving forward.